Drugs / PvCS/Montanide ISA-51 VG Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07373301 | Jan 2026 → Jul 2027 expected | Plasmodium vivax malaria | Malaria Vaccine and Drug Development Center | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PvCS/Montanide ISA-51 VG Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07373301 ↗ |
| Modality | Vaccine | “The investigational vaccine (PvCS) contains synthetic peptides derived from the circumsporozoite (CS) protein located on the surface of P. vivax sporozoites.” NCT07373301 ↗ |
| Route | Intramuscular | “The study product will be administered by intramuscular injection at months 0, 2, and 4.” NCT07373301 ↗ |